Figure S1. CONSORT flow diagram.

Twenty-two PD patients were initially recruited to participate in an intention-to-treat trial. One patient failed to meet inclusion criteria and another was excluded due to inability to provide blood by venipuncture. Twenty patients were randomized, and 10 patients were allocated to receive sargramostim and 10 to receive placebo. In the sargramostim-treated group, 2 withdrew due to chest-tightness or bone pain, 1 withdrew due to leukoclastic vasculitis, and 1 withdrew due to a urticarial response.